BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
See today's BioWorld Asia
Home
» Lee's sets sights on dry eye, gets fast track CFDA phase II approval
To read the full story,
subscribe
or
sign in
.
Lee's sets sights on dry eye, gets fast track CFDA phase II approval
June 25, 2014
By
Shannon Ellis
SHANGHAI – Another month, another announcement for Lee's Pharmaceuticals Ltd., of Hong Kong, as it has been slowly but surely building a successful biotech business and developing and commercializing products for the China market.
BioWorld Asia